The estimated Net Worth of David Shapiro is at least $14.9 Million dollars as of 1 May 2019. David Shapiro owns over 2,000 units of Galecto stock worth over $544,467 and over the last 12 years David sold GLTO stock worth over $14,388,828.
David has made over 62 trades of the Galecto stock since 2013, according to the Form 4 filled with the SEC. Most recently David exercised 2,000 units of GLTO stock worth $63,800 on 1 May 2019.
The largest trade David's ever made was exercising 11,426 units of Galecto stock on 18 December 2015 worth over $199,955. On average, David trades about 2,361 units every 25 days since 2012. As of 1 May 2019 David still owns at least 41,499 units of Galecto stock.
You can see the complete history of David Shapiro stock trades at the bottom of the page.
David's mailing address filed with the SEC is OLE MAALOES VEJ 3, C/O GALECTO, INC., COPENHAGEN N G7, G7, DK-2200.
Over the last 4 years, insiders at Galecto have traded over $2,298,261 worth of Galecto stock and bought 1,911,769 units worth $28,139,830 . The most active insiders traders include Holdings A/S Novo, Chau Quang Khuong, and Carl Goldfischer. On average, Galecto executives and independent directors trade stock every 46 days with the average trade being worth of $2,037,418. The most recent stock trade was executed by Advisors Llc Orbi Med Genes... on 15 August 2023, trading 822,680 units of GLTO stock currently worth $617,010.
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
Galecto executives and other stock owners filed with the SEC include: